Home > Insider Trading > Filing (0000950170-24-024970)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1029142	Dynavax Technologies Corp	DVAX	Pharmaceutical Preparations (2834)	330728374

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1812025	Justin Burgess	C/O Dynavax Technologies 2100 Powell Street, Suite 720 Emeryville CA 94608	Chief Accounting Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-01	4,334	$11.12	17,759	No	4	M	Direct
Common Stock	Acquisiton	2024-03-01	2,767	$9.41	20,526	No	4	M	Direct
Common Stock	Disposition	2024-03-01	7,101	$12.78	13,425	No	4	S	Direct
Common Stock	Disposition	2024-03-01	13,425	$12.78	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2024-03-01	4,334	$0.00	0	$11.12
Common Stock	StockOptions (Right to Buy)	Disposition	2024-03-01	2,767	$0.00	0	$9.41

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
8,666		2030-02-15	No	4	M	Direct
0		2028-02-02	No	4	M	Direct

Footnotes

Code M - Exercise or conversion of derivative security
Code S - Open market or private sale of non-derivative or derivative security
This transaction was executed in multiple trades at prices ranging from $12.73 to $12.81; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 3, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.